AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33341314
Drug: 24-h urinary
RxNorm normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-h urinary creatinine excretion rate (CER)
Trial: 33341407
Drug: IV tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV tobramycin (10 mg/kg/d, ≥10 days)
Trial: 33341448
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D deficiency (serum levels <25 nmol/L)
Trial: 33341448
Drug: Sufficient vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufficient vitamin D levels (serum levels >50 nmol/L)
Trial: 33341870
Drug: Cord-blood IgG
RxNorm normalized name: human cord blood hematopoietic progenitor cell
DrugBank: Human cord blood hematopoietic progenitor cell (DB11054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cord-blood IgG concentrations ≥1.04 µg/mL for serotype Ia
Trial: 33341870
Drug: Cord-blood IgG
RxNorm normalized name: human cord blood hematopoietic progenitor cell
DrugBank: Human cord blood hematopoietic progenitor cell (DB11054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cord-blood IgG concentrations ≥1.53 µg/mL for serotype III
Trial: 33341870
Drug: Maternal sera
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal sera IgG threshold ≥2.31 µg/mL for serotype Ia
Trial: 33341870
Drug: Maternal sera
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal sera IgG threshold ≥3.41 µg/mL for serotype III
Trial: 33341883
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral PrEP (emtricitabine 200 mg/tenofovir diphosphate 300 mg) administered for 12 weeks
Trial: 33342078
Drug: Topical pain
RxNorm normalized name: Flex24 Topical Pain Patch
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical pain medication
Trial: 33343498
Drug: Motor therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motor therapy
Trial: 33344227
Drug: Nivolumab 240
RxNorm normalized name: nivolumab 240 MG in 24 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 240 mg intravenously on days 1 and 15 with or without oral tadalafil
Trial: 33344752
Drug: Intravenous allopregnanolone
RxNorm normalized name: Allopregnanolone
DrugBank: Brexanolone (DB11859)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous allopregnanolone (2 mg, 4 mg, 6 mg, and 10 mg) administered once-per-week for 12 weeks
Trial: 33344752
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered once-per-week for 12 weeks
Trial: 33344752
Drug: Intravenous allopregnanolone
RxNorm normalized name: Allopregnanolone
DrugBank: Brexanolone (DB11859)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous allopregnanolone (various dosages)
Trial: 33344885
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment according to Brain Trauma Foundation guidelines
Trial: 33345095
Drug: Antioxidant-rich foods;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant-rich foods; specific dosage and duration not available.
Trial: 33345877
Drug: Ratio of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ratio of insulin-like growth factor-binding protein 4 to sex hormone-binding globulin
Trial: 33345934
Drug: Personal gestational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personal gestational weight gain goal consistent with Institute of Medicine recommendations
Trial: 33345967
Drug: Invu system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invu system (wireless, wearable, self-administered device)
Trial: 33346007
Drug: PPI therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI therapy (pantoprazole 40 mg once daily for 4 weeks)
Trial: 33346007
Drug: PPI therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI therapy in HVs
Trial: 33346428
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitors (PPIs) prescribed in 28.3% of cases; 90.2% of patients with UGI bleeding received PPI.
Trial: 33346428
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy for 6-12 months after elective PCI.
Trial: 33346510
Drug: Indirect cold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indirect cold atmospheric plasma (CAP) treatment for 3 months
Trial: 33346510
Drug: Indirect cold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indirect cold atmospheric plasma (CAP) treatment for 6 months
Trial: 33346510
Drug: Investigator's assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's assessment of indirect CAP treatment
Trial: 33347715
Drug: 225Ac-labeled CD33-targeting
RxNorm normalized name: 225Ac-HuM195
DrugBank: Lintuzumab satetraxetan AC-225 (DB15053)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 225Ac-labeled CD33-targeting antibody
Trial: 33348999
Drug: Statins (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statins (specific type, dosage, and duration not available)
Trial: 33348999
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (specific treatment or placebo not available)
Trial: 33349123
Drug: CAR T
RxNorm normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAR T cell therapy combined with oncolytic viruses (OVs)
Trial: 33350618
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 20% albumin at 3 mL/kg over 30 minutes
Trial: 33351103
Drug: α-1-antitrypsin (AAT)
RxNorm normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-1-antitrypsin (AAT) treatment
Trial: 33351775
Drug: Home-use smell
RxNorm normalized name: egg shell membrane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-use smell and taste test kit for daily self-assessments over 28 days
Trial: 33352201
Drug: Copanlisib (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copanlisib (60 mg) + Gemcitabine (1000 mg/m²)
Trial: 33352296
Drug: Direct acting
RxNorm normalized name: DIRECT ACTING ANTIVIRALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct acting antiviral therapy
Trial: 33354862
Drug: BI 409306
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 409306 50 mg twice daily for 52 weeks
Trial: 33355238
Drug: MK-4166 900
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-4166 900 mg i.v. every 3 weeks as monotherapy
Trial: 33355238
Drug: MK-4166 with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-4166 with pembrolizumab 200 mg i.v. every 3 weeks for ≤35 doses
Trial: 33355273
Drug: Direct oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral anticoagulants (DOACs) - dabigatran, rivaroxaban, apixaban
Trial: 33355914
Drug: Dolutegravir 50
RxNorm normalized name: dolutegravir 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir 50 mg (DTG)-based regimen
Trial: 33355914
Drug: Low-dose Efavirenz
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Efavirenz 400 mg (EFV400)-based regimen
Trial: 33356019
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral 100-mg glasdegib dose under fasted conditions
Trial: 33357452
Drug: Immunogenic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunogenic chemotherapy combined with checkpoint blockade
Trial: 33358103
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment with aortic endoprosthesis
Trial: 33359404
Drug: Standard second-line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard second-line doublet chemotherapy plus a targeted agent
Trial: 33360365
Drug: Mobile-enhanced family-focused
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile-enhanced family-focused therapy (FFT) with a mobile app (12 sessions in 18 weeks)
Trial: 33361296
Drug: Fluconazole (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (dosage not specified) as prophylaxis or treatment
Trial: 33361296
Drug: Fluconazole (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (dosage not specified)
Trial: 33361303
Drug: Dihydroartemisinin-piperaquine (DP)
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine (DP) administered in standard 3-day courses at 4- to 8-week intervals from the second trimester until delivery.
Trial: 33362485
Drug: Ketamine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine treatment for AUD, specific dosage and duration not mentioned.
Trial: 33369580
Drug: PARP inhibitors
RxNorm normalized name: Poly (ADP-ribose) polymerase (PARP) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PARP inhibitors (PARPi)
Trial: 33371015
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tests (VIA, Gynocular, HR-HPV)
Trial: 33371020
Drug: Standard-of-care (SOC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care (SOC) therapy
Trial: 33371779
Drug: 1% IQP-0528
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% IQP-0528 gel (10 mL rectal dose)
Trial: 33373024
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (ET) in OAC patients
Trial: 33373873
Drug: Epidermal growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidermal growth factor receptor (EGFR) inhibition
Trial: 33373873
Drug: Drugs inhibiting
RxNorm normalized name: C1-inhibiting factor
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs inhibiting TNF
Trial: 33374003
Drug: Nephritogenic IgG2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nephritogenic IgG2 antibodies
Trial: 33376109
Drug: Sirolimus treatment
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus treatment for 6 months at plasma concentration levels of 5-8 µg/L
Trial: 37153086
Drug: Sirolimus treatment
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus treatment for 6 months
Trial: 33376169
Drug: High CRP
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High CRP level (>10 mg/L) at discharge
Trial: 33376169
Drug: Low CRP
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low CRP level (≤10 mg/L) at discharge
Trial: 33376179
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clinical, functional and circulating biomarkers
Trial: 33376186
Drug: Masculinising testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Masculinising testosterone treatment
Trial: 33376319
Drug: Daily step
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily step count measurement using an activity monitor over 14 consecutive days.
Trial: 33377134
Drug: PD-1 x
RxNorm normalized name: Pd-1 x ctla-4 dual checkpoint inhibitor xmab20717
DrugBank: Vudalimab (DB18833)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 x CTLA-4 bispecific DART molecule (MGD019)
Trial: 33377134
Drug: Combination immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination immunotherapy with antibodies directed against PD-1 and CTLA-4
Trial: 33377134
Drug: Single agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single agents (PD-1 or CTLA-4 antibodies)
Trial: 33378384
Drug: High-dose fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose fluticasone propionate
Trial: 33378384
Drug: Both low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both low and high-dose ICS
Trial: 33380478
Drug: Intraocular pressure-lowering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraocular pressure-lowering therapy (specific details not provided)
Trial: 33380478
Drug: Detailed ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detailed ophthalmic examinations (specific details not provided)
Trial: 33382032
Drug: Positive airway
RxNorm normalized name: VersaPAP Positive Airway Pressure Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive airway pressure therapy; Treatment adherence rate: 55% at 1 year.
Trial: 33382032
Drug: Positional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positional therapy and opioids/sedative reduction; Treatment received by the rest of the patients with sleep apnea.
Trial: 33382032
Drug: Not applicable;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not applicable; High refusal rate for treatment.
Trial: 33382405
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) initiated on the day of enrollment for 171 (87.7%) participants.
Trial: 33382405
Drug: Nonreactive or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonreactive or indeterminate HIV antibody on the Geenius assay combined with ARCHITECT S/CO ≥10.
Trial: 33383350
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of testosterone cypionate intramuscularly every 28 days concurrent with a luteinising hormone-releasing hormone agonist/antagonist
Trial: 33383350
Drug: bipolar androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bipolar androgen therapy (BAT)
Trial: 33385020
Drug: Probiotics; specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics; specific dosage and duration not available
Trial: 38870745
Drug: Treatment-related adverse
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-related adverse events (TRAEs)
Trial: 33388360
Drug: External Radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External Radiation Therapy
Trial: 33388985
Drug: Cochlear implant
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cochlear implant fitting methodology and parameters
Trial: 33389209
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of various normalization methods
Trial: 33389388
Drug: Ulixertinib (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulixertinib (10 to 900 mg in dose escalation cohort, 600 mg in 21-day cycles in expansion cohort)
Trial: 33389459
Drug: Low salt-low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low salt-low protein diet (0.6 g/kg-day) supplemented with keto-analogues (sLPD) under intensive nutritional counselling
Trial: 33389656
Drug: Carfilzomib (27
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib (27 mg/m²) administered twice weekly
Trial: 33390782
Drug: RIST treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIST treatment protocol (combination of Rapamycin and Dasatinib with Irinotecan and Temozolomide)
Trial: 33391002
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml of 5% dextrose water
Trial: 33391002
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml of 5% dextrose water
Trial: 33391002
Drug: 4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml of 5% dextrose water
Trial: 33392485
Drug: INO-4800 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INO-4800 1.0 mg
Trial: 33392485
Drug: INO-4800 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INO-4800 2.0 mg
Trial: 33392541
Drug: Fish oil-containing
RxNorm normalized name: fish oil (containing omega-3 acids)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil-containing lipid injectable emulsion (Smoflipid 20% lipid emulsion) administered at doses of 1.0 to 1.6 g/kg within 48 hours of enrollment.
Trial: 34920917
Drug: Cabozantinib 60
RxNorm normalized name: cabozantinib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 60 mg once daily
Trial: 33393488
Drug: Atorvastatin and
RxNorm normalized name: atorvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin and Nonstatin users (Control)
Trial: 33394121
Drug: Higher dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher dietary zinc intake (8.4±4.5 mg/day) from non-red meat sources
Trial: 33399311
Drug: PrEP maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PrEP maintenance (87% adherence to 4+ doses per week)
Trial: 33399372
Drug: mini-fluid challenge
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mini-fluid challenge (mini-FC) of 100 ml over 1 min
Trial: 33399383
Drug: 50% inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% inhaled N2O
Trial: 33399383
Drug: 25% inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% inhaled N2O
Trial: 33399511
Drug: MRI-guided focused
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI-guided focused ultrasound-induced BBB opening targeting the hippocampus and entorhinal cortex, performed three times at 2-week intervals using a 220-kHz transducer and intravenous microbubble contrast agent.
Trial: 33400777
Drug: Direct-acting antiviral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct-acting antiviral agents (DAA) treatment
Trial: 33402222
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of brown flaxseed (30 g milled) and hesperidin (two 500 mg capsules) during lifestyle intervention
Trial: 33402222
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of brown flaxseed and hesperidin
Trial: 33402692
Drug: SSTR2 targeting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSTR2 targeting using PEN-221, a cytotoxic drug conjugate.
Trial: 33403007
Drug: nal-IRI 50
RxNorm normalized name: IRIS TENAX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nal-IRI 50 mg/m² with fluorouracil/leucovorin (5-FU/LV) and oxaliplatin, administered in three cycles before and three cycles after surgical resection
Trial: 33403401
Drug: Drugs used
RxNorm normalized name: DRUGS USED IN DIABETES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs used to prevent CIPN (B vitamins, calcium and magnesium infusion)
Trial: 33403401
Drug: Therapeutic adjustment
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic adjustment of neurotoxic anticancer drugs
Trial: 33403831
Drug: Mineralocorticoid receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineralocorticoid receptor antagonist (MRA) added to conventional anti-failure therapy
Trial: 33404519
Drug: 1.0 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/day entecavir
Trial: 33405950
Drug: High EOI
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High EOI MRD with AML-like consolidation therapy
Trial: 33405951
Drug: Average-risk treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average-risk treatment group
Trial: 33405951
Drug: High-risk treatment
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-risk treatment group
Trial: 33406328
Drug: Sitagliptin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin (600 mg every 12 hours starting the day before transplantation until day 14 after transplantation) plus tacrolimus and sirolimus
Trial: 33407685
Drug: Fingolimod treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod treatment for 12 months